Dante Labs Partners With Al Farabi Medical Labs in Saudi Arabia To Offer Genomic Testing in the Saudi Kingdom
Dante Labs, a global leader in genomics and precision medicine, and Al Farabi Medical Laboratories, the leading medical laboratory in the Kingdom of Saudi Arabia with more than 50 labs covering all regions of the Kingdom, are pleased to announce a commercial partnership to provide patients with a wide range of clinical genomic tests. These tests include Whole Genome Sequencing and Whole Exome Sequencing with interpretation, as well as Non-Invasive Prenatal Testing (NIPT) in Saudi Arabia.
Andrea Riposati, CEO and co-founder of Dante Labs, stated that they are overjoyed to provide sophisticated genetic testing services in conjunction with the Al Farabi Medical Labs in the Kingdom of Saudi Arabia. “We are thrilled to offer these services. We are most excited to be able to contribute to the continued success of Al Farabi Medical Labs and the innovative work they do. Together, we aim to make it possible for Saudi Arabian individuals to get healthcare driven by whole-genome sequencing.”
Dr. Mohamed Marie, founder, and general manager of Al Farabi, stated that their company was proud to harness the technology and experience offered by Dante Labs in the Kingdom of Saudi Arabia. A market leader in the medical testing industry, Al Farabi has more than 50 locations spread all over the Kingdom. Dr. Mohamed Marie said, “Our collaboration with Dante Labs will involve genetic testing as well as other genomic-based solutions. As we have achieved over the years across the board in healthcare, our goal is to provide our patients with services of the greatest possible quality, and that includes genomics.”
More on Dante Labs
Dante Labs is a worldwide genomic information company that is developing and monetizing a new category of transformational health and longevity apps founded on whole genetic testing and artificial intelligence. These applications will help people live healthier and longer lives. Through the usage of its platform, the company is able to provide improved patient outcomes, enhanced diagnostics, individualized treatment, and preventative measures. The company’s assets include one of the biggest private genome databases with research consent attached to it, patented software designed to unleash the potential of genomic data at scale, and proprietary techniques that enable an industrialized approach to gene sequencing.
More on Al Farabi Medical Labs
Since the company’s inception, Al Farabi Medical Labs has pursued the policy of enticing and localizing the new and contemporary in various diagnostic techniques in order to work on challenging equations in the medical sector in terms of the level of performance, speed of results, and fair price for the service that is provided. This policy is still in place today. Since its inception, Al Farabi Medical Labs has adhered to a stringent policy that mandates compliance with worldwide as well as local norms and requirements for the quality of laboratory work and the protection of employees. Consequently, the CBAHI and JCI accreditations (national and worldwide, respectively) have been successfully obtained.